Hims & Hers Health (NYSE:HIMS) Insider Sells $114,486.63 in Stock

Key Points

• Insider Soleil Boughton sold 2,571 shares of Hims & Hers Health stock for a total of $114,486.63, decreasing their position by 1.68% and leaving them with 150,450 shares worth approximately $6.7 million.
• The stock's price fluctuated, recently reaching $45.50 after trading up by $2.51, with a 12-month high of $72.98 and a low of $13.47.
• For the most recent quarter, Hims & Hers reported an EPS of $0.17, missing estimates, although revenue was up 72.6% year-over-year at $544.83 million.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Soleil Boughton sold 2,571 shares of the stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $44.53, for a total transaction of $114,486.63. Following the completion of the transaction, the insider owned 150,450 shares in the company, valued at approximately $6,699,538.50. This trade represents a 1.68% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Soleil Boughton also recently made the following trade(s):

• On Monday, August 11th, Soleil Boughton sold 2,572 shares of Hims & Hers Health stock. The stock was sold at an average price of $51.64, for a total transaction of $132,818.08.
• On Monday, July 28th, Soleil Boughton sold 2,572 shares of Hims & Hers Health stock. The stock was sold at an average price of $58.70, for a total transaction of $150,976.40.
• On Monday, July 14th, Soleil Boughton sold 2,572 shares of Hims & Hers Health stock. The stock was sold at an average price of $47.82, for a total transaction of $122,993.04.
• On Monday, June 30th, Soleil Boughton sold 2,572 shares of Hims & Hers Health stock. The stock was sold at an average price of $50.50, for a total transaction of $129,886.00.
• On Tuesday, June 17th, Soleil Boughton sold 2,572 shares of Hims & Hers Health stock. The stock was sold at an average price of $59.75, for a total transaction of $153,677.00.
• On Monday, June 16th, Soleil Boughton sold 5,451 shares of Hims & Hers Health stock. The stock was sold at an average price of $56.80, for a total value of $309,616.80.

Hims & Hers Health Stock Performance

Hims & Hers Health stock traded up $2.51 during mid-day trading on Tuesday, hitting $45.50. The company had a trading volume of 29,293,931 shares, compared to its average volume of 33,600,738. The company has a current ratio of 4.98, a quick ratio of 4.46 and a debt-to-equity ratio of 1.72. Hims & Hers Health, Inc. has a 12-month low of $13.47 and a 12-month high of $72.98. The company's fifty day moving average is $51.37 and its 200-day moving average is $45.85. The company has a market capitalization of $10.28 billion, a price-to-earnings ratio of 56.88, a P/E/G ratio of 3.01 and a beta of 2.08.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The company had revenue of $544.83 million during the quarter, compared to analysts' expectations of $550.06 million. During the same quarter in the prior year, the company posted $0.06 EPS. The company's revenue for the quarter was up 72.6% on a year-over-year basis. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities research analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have commented on HIMS. Piper Sandler restated a "neutral" rating and issued a $39.00 price objective (up previously from $35.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Morgan Stanley restated an "equal weight" rating and issued a $40.00 price objective on shares of Hims & Hers Health in a research report on Wednesday, June 11th. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Hims & Hers Health in a research report on Wednesday, May 7th. TD Cowen lowered Hims & Hers Health from a "buy" rating to a "hold" rating and decreased their target price for the company from $44.00 to $30.00 in a research report on Tuesday, April 29th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Hims & Hers Health in a research report on Tuesday, August 5th. Two analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, Hims & Hers Health has an average rating of "Reduce" and a consensus price target of $38.92.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HIMS. Virtus Advisers LLC purchased a new position in Hims & Hers Health in the 2nd quarter valued at $26,000. Quaker Wealth Management LLC purchased a new position in Hims & Hers Health in the 2nd quarter valued at $29,000. Bessemer Group Inc. lifted its holdings in Hims & Hers Health by 105.8% in the 2nd quarter. Bessemer Group Inc. now owns 607 shares of the company's stock valued at $30,000 after purchasing an additional 312 shares in the last quarter. Geneos Wealth Management Inc. purchased a new position in Hims & Hers Health in the 1st quarter valued at $30,000. Finally, Skandinaviska Enskilda Banken AB publ lifted its holdings in Hims & Hers Health by 408.2% in the 2nd quarter. Skandinaviska Enskilda Banken AB publ now owns 747 shares of the company's stock valued at $37,000 after purchasing an additional 600 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company's stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.